AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28238761
DOI
10.1016/j.yexmp.2017.02.016
PII: S0014-4800(16)30276-3
Knihovny.cz E-zdroje
- Klíčová slova
- AGR2, Breast cancer, HER2,
- MeSH
- lidé MeSH
- messenger RNA genetika metabolismus MeSH
- mukoproteiny MeSH
- nádorové buněčné linie MeSH
- nádory prsu diagnóza genetika MeSH
- onkogenní proteiny MeSH
- prognóza MeSH
- proliferace buněk MeSH
- proteiny genetika metabolismus MeSH
- receptor erbB-2 genetika MeSH
- receptory pro estrogeny genetika MeSH
- regulace genové exprese u nádorů * MeSH
- upregulace MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- AGR2 protein, human MeSH Prohlížeč
- ERBB2 protein, human MeSH Prohlížeč
- messenger RNA MeSH
- mukoproteiny MeSH
- onkogenní proteiny MeSH
- proteiny MeSH
- receptor erbB-2 MeSH
- receptory pro estrogeny MeSH
Expression of the AGR2 oncogene was shown to be associated with estrogen receptor positive tumors. This gene contributes to enhanced cellular proliferation, drug resistance, metastasis development and may also serve as a predictor of poor prognosis. However, our analysis of AGR2 expression in a subset of estrogen-receptor negative tumors revealed that AGR2 could also be upregulated in hormone-independent manner. AGR2 expression was shown to be significantly increased in HER2 positive breast tumors on both the mRNA and the protein level. Moreover, in a subset of estrogen- and progesterone-receptor negative and simultaneously HER2-positive cases, increased AGR2 expression significantly correlated with worse patient prognosis. Subsequent analysis of independent data sets either collected in our institute or obtained from Oncomine cancer microarray database confirmed all these findings.
Citace poskytuje Crossref.org
